183 related articles for article (PubMed ID: 24617955)
1. Case of vemurafenib-induced Sweet's syndrome.
Yorio JT; Mays SR; Ciurea AM; Cohen PR; Wang WL; Hwu WJ; Gonzalez N; Richard JL; Kim KB
J Dermatol; 2014 Sep; 41(9):817-20. PubMed ID: 24617955
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib-induced neutrophilic panniculitis.
Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
5. [Vemurafenib-induced toxic epidermal necrolysis].
Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
[TBL] [Abstract][Full Text] [Related]
6. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib-induced Sweet's syndrome.
Fye KH; Crowley E; Berger TG; LeBoit PE; Connolly MK
J Am Acad Dermatol; 2001 Aug; 45(2):300-2. PubMed ID: 11464196
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.
Conen K; Mosna-Firlejczyk K; Rochlitz C; Wicki A; Itin P; Arnold AW; Gross M; Zimmermann F; Zippelius A
Dermatology; 2015; 230(1):1-4. PubMed ID: 25472806
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib-induced bilateral facial palsy.
Shailesh FN; Singh M; Tiwari U; Hutchins LF
J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
12. Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature.
Yaşar HA; Akkus E; Heper A; Akay BN; Urun Y; Utkan G
J Oncol Pharm Pract; 2020 Oct; 26(7):1762-1764. PubMed ID: 32089071
[TBL] [Abstract][Full Text] [Related]
13. Analysis of dermatologic events in vemurafenib-treated patients with melanoma.
Lacouture ME; Duvic M; Hauschild A; Prieto VG; Robert C; Schadendorf D; Kim CC; McCormack CJ; Myskowski PL; Spleiss O; Trunzer K; Su F; Nelson B; Nolop KB; Grippo JF; Lee RJ; Klimek MJ; Troy JL; Joe AK
Oncologist; 2013; 18(3):314-22. PubMed ID: 23457002
[TBL] [Abstract][Full Text] [Related]
14. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.
Pintova S; Sidhu H; Friedlander PA; Holcombe RF
Melanoma Res; 2013 Dec; 23(6):498-501. PubMed ID: 24113862
[TBL] [Abstract][Full Text] [Related]
15. Early-Onset Vemurafenib-Induced DRESS Syndrome.
Munch M; Peuvrel L; Brocard A; Saint Jean M; Khammari A; Dreno B; Quereux G
Dermatology; 2016; 232(1):126-8. PubMed ID: 26418832
[TBL] [Abstract][Full Text] [Related]
16. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
Regnier-Rosencher E; Lazareth H; Gressier L; Avril MF; Thervet E; Dupin N
Br J Dermatol; 2013 Oct; 169(4):934-8. PubMed ID: 23909652
[TBL] [Abstract][Full Text] [Related]
17. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
18. Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration.
Maximova N; Maestro A; Zanon D; Marcuzzi A
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066648
[TBL] [Abstract][Full Text] [Related]
19. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
20. Quinupristin/dalfopristin-induced Sweet's syndrome.
Choi HS; Kim HJ; Lee TH; Lee SH; Lee TW; Ihm CG; Kim MJ
Korean J Intern Med; 2003 Sep; 18(3):187-90. PubMed ID: 14619389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]